Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-768-6 | CAS number: 5064-31-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
In an absorption and excretion study according to OECD 417 Na3NTA was administered to male Wistar rats at dose levels of 500 mg/kg and 25 mg/kg (BASF, 1997). Na3NTA was rapidly absorbed from the gastrointestinal tract after single and repeated oral administration. Absorption, however, was incomplete amounting to about 50 % of the dose applied. Excretion was rapid with a urinary excretion half-life of about 5-6 hours. The experiment did not indicate any bioaccumulation potential.
In beagle dogs absorption of 20 mg/kg Na2NTA was extensive and rapid (Budny, 1972). 80% of oral applied NTA appeared in the urine after 72h. 75 % after 4 hr. Peak concentration in blood was reached after 75 min. Since 96 % of an i.v. administered dose appeared in the urine, with only a negligible amount in the feces, it can be concluded that no enterohepatic circulation occurred. The rapid and extensive excretion is consistent with the low overall tissue deposition of NTA. The greatest tissue deposition was in bones (2-3 pg/g); the next highest in the kidneys.
A combined toxicokinetic/teratologinicity study in mice showed that the distribution patterns of i.v. injection and p.o. administration were similar and characterized by high uptake of radioactivity in the skeleton compared to other compartments (Tjälve 1972). The radioactivity was rapidly accumulated and was still present after 48 hours. In pregnant mice, a low uptake of the test substance also in the skeleton of fetuses could be observed and in addition to a comparable high accumulation in the walls of the uterus. Although a low percentage of NTA was deposited in the skeleton, no clear adverse effect of NTA treatment on the bone was seen in rats in a 2-year feeding study at concentrations of up to 322 mg/kg/d (Nixon et al., 1972; section 7.5.1) or in fetal development (Tjälve, 1972; section7.8.2). An examination in bones showed a dose-related increased NTA content. Histological examination of bone showed no differences in the amount of osteoid tissue or widths of the epiphyseal plates between samples from control animals and animals of the high dose group (Budny 1973; section 7.5.1).
Budny & Arnold (1973) examined the oral absorption of Na3NTA in 8 human volunteers (IUCLID section 7.10.3). NTA was poorly absorbed and rapidly excreted as indicated by a fraction of 12% recovered in Urin within 120 h (77% recovered in feces). Blood concentration peak occurred within 1 -2 h. After 12 h only traces of radioactivity were found in blood. NTA was not metabolized to a significant extend. > 96% of the urinay radioactivity was found to be uncharged NTA. There was no evidence for enterohepatic circulation.
The human data suggest a pronounced species differences: 12% of the total dose was excreted in human urine in 2h. This was 87% of the absorbed dose (77% were recovered in feces). An absorption rate for human between 10 and 20 % was concluded. In contrast in dogs only 3% of the applied dose was recovered in the feces. Up to 97% were absorbed and rapidly excreted in urine. In rats only approximately 50% of the applied dose was absorbed, 80% of this dose was excreted in urine in 24h. These data suggest that human absorption rate is 1/4 of the that observed in rats or dogs.
Data on dermal absorption are not available form animal studies or reported in humans. However, dermal penetration was assessed in vitro (BASF 2008).14C-Na3NTA was applied to human skin preparations in a Franz-type diffusion cells as 40 % and 1% aqueous dilution. At high concentration exposure was stopped after 5 min to avoid severe skin damage that would greatly enhance penetration. 0.001 % (n=5) of the substance was absorbed. However, the applied dose was washed off after 5 min in this setting, so this experimental data do not allow drawing conclusions on elongated exposure to 40% Na3NTA. At low concentration exposure was stopped after 6 h. Absorption ranged between 0.042 and 0.472 % (n=5) during a sampling period of 24 hr. The presence of a lag time of absorption (about 1.6 h) underlines the functional diffusion barrier of human skin against NTA preparation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.